This ticker has not been starred yet INMB Inmune Bio, Inc.
Biological Products (no Diagnostic Substances)
Book value per $ invested $ 0.49
Leverage 26.73%
Market Cap $ 79.7m
PE 0.00
Dividend Yield 0.00%
Profit $ -41.1m
Margin 3783.98%

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patients innate immune system to treat cancer, Alzheimers disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.

Subscribe Now For Access - Only $1.99 Per Month